Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2015-06-24

FDA Approved: ORACEA — Supplemental Application (Galderma Laboratories, L.P.)

View source ↗

Summary

FDA supplemental approval for Oracea (doxycycline) under Galderma, indicating a labeling change related to the supplemental application.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ORACEA (Doxycycline)

Snippet

SUPPL AP for ORACEA (DOXYCYCLINE)